JPS61286362A - Amidine compound - Google Patents
Amidine compoundInfo
- Publication number
- JPS61286362A JPS61286362A JP12834085A JP12834085A JPS61286362A JP S61286362 A JPS61286362 A JP S61286362A JP 12834085 A JP12834085 A JP 12834085A JP 12834085 A JP12834085 A JP 12834085A JP S61286362 A JPS61286362 A JP S61286362A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- formula
- acid
- compound
- amidino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Amidine compound Chemical class 0.000 title abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 27
- 239000003795 chemical substances by application Substances 0.000 abstract description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 16
- ULKSSXOMKDEKPC-UHFFFAOYSA-N 6-hydroxynaphthalene-2-carboximidamide Chemical compound C1=C(O)C=CC2=CC(C(=N)N)=CC=C21 ULKSSXOMKDEKPC-UHFFFAOYSA-N 0.000 abstract description 14
- 239000002904 solvent Substances 0.000 abstract description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000002391 anti-complement effect Effects 0.000 abstract description 3
- 230000000288 anti-kallikrein effect Effects 0.000 abstract description 3
- 108010008730 anticomplement Proteins 0.000 abstract description 3
- 239000004019 antithrombin Substances 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 101710081722 Antitrypsin Proteins 0.000 abstract description 2
- 108010028774 Complement C1 Proteins 0.000 abstract description 2
- 206010018910 Haemolysis Diseases 0.000 abstract description 2
- 206010033645 Pancreatitis Diseases 0.000 abstract description 2
- 208000007536 Thrombosis Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000001475 anti-trypsic effect Effects 0.000 abstract description 2
- 230000008588 hemolysis Effects 0.000 abstract description 2
- 201000008383 nephritis Diseases 0.000 abstract description 2
- 239000002753 trypsin inhibitor Substances 0.000 abstract description 2
- 102000016917 Complement C1 Human genes 0.000 abstract 1
- 239000007806 chemical reaction intermediate Substances 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012048 reactive intermediate Substances 0.000 description 3
- NCVIXRFLZFTMOS-UHFFFAOYSA-N (6-carbamimidoylnaphthalen-2-yl) methanesulfonate Chemical compound C1=C(C(N)=N)C=CC2=CC(OS(=O)(=O)C)=CC=C21 NCVIXRFLZFTMOS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- GAVZNOLUZPCABT-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboximidamide Chemical compound NC(=N)c1c(O)ccc2ccccc12 GAVZNOLUZPCABT-UHFFFAOYSA-N 0.000 description 1
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は式(1)
(式中、RoおよびR2は各々水素または炭素数1〜6
個の直鎖または分枝鎖アルキル基金示し、R3は炭素数
1〜6個の直鎖または分枝鎖アルキル基を示すか、ある
いはRよとR3は環を形成してもよく、その場合二重結
合を介してもよく、R4は炭素数1〜6個の直鎖または
分枝鎖アルキル基、アルコキシ基またはハロゲノを示す
)で示されるアミジン化合物およびその医薬と(2て使
用可能な酸付加塩に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the formula (1) (wherein Ro and R2 are each hydrogen or a carbon number of 1 to 6
R3 represents a straight-chain or branched alkyl group having 1 to 6 carbon atoms, or R and R3 may form a ring, in which case The amidine compound represented by R4 represents a linear or branched alkyl group having 1 to 6 carbon atoms, an alkoxy group, or a halogeno group, and its pharmaceuticals (2) may be formed through a double bond, and R4 represents a straight or branched alkyl group having 1 to 6 carbon atoms, Regarding salt.
本発明の目的は、医薬として有用な新規なアミジン化合
物および医薬として使用可能な酸付加塩を提供すること
にある。An object of the present invention is to provide novel amidine compounds useful as pharmaceuticals and acid addition salts usable as pharmaceuticals.
本発明の他の目的は新規なアミジン化合物の製造方法を
提供することにある。Another object of the present invention is to provide a novel method for producing amidine compounds.
本発明の他の目的は強い抗トリプシン剤、抗プラスミン
剤、抗カリクレイン剤、および抗スロンビン剤を提供す
ることにある。Another object of the present invention is to provide strong antitrypsin, antiplasmin, antikallikrein, and antithrombin agents.
本発明の他の目的は強い抗補体剤を提供することにある
。Another object of the invention is to provide strong anti-complement agents.
本発明化合物(I)は式(11)で示されるカルボン酸
化合物又はその反応性中間体と式(1)で示される6−
アミジノ−2−ナフトール、好ましくはその酸付加塩を
反応させることにより製造することができる。The compound (I) of the present invention is a carboxylic acid compound represented by formula (11) or a reactive intermediate thereof and a 6-
It can be produced by reacting amidino-2-naphthol, preferably its acid addition salt.
(:R1,R2,R3およびR4は前述の通りである)
ここでいう反応性中間体とは通常の脱水縮合反応に用い
られる酸ハライP1酸無水物およびジシクロへキシルカ
ーポジイミド(DOO) 、ジフェニルホスホリルアジ
ド(DPPA)等とカルボン酸誘導体との反応によって
得られる反応性間体全示す。(:R1, R2, R3 and R4 are as described above)
The reactive intermediate referred to here is obtained by the reaction of acid halide P1 acid anhydride, dicyclohexylcarposiimide (DOO), diphenylphosphoryl azide (DPPA), etc. used in normal dehydration condensation reactions with carboxylic acid derivatives. The entire reactive body is shown.
本発明の化合物の製造方法についてさらに詳細に述べる
。The method for producing the compound of the present invention will be described in more detail.
カルボン酸誘導体(n) ’!にジメチルボルムアミド
、ピリジン等の有機溶媒に溶解又はけん濁し、通常脱水
縮合剤として用いられるジシクロへキシルカー4ぐジイ
ミド(DOO) 、ジフェニルホスボリルアジド(DP
PA)等のエステル活性化剤と反応させ、ことに6−ア
ミジノ−2−ナフトール、好ましくはその酸付加塩を加
えることによって、本発明化合物(1) ’e得ること
ができる。Carboxylic acid derivative (n)'! dicyclohexylcardiimide (DOO), diphenylphosphoryl azide (DP), which is usually used as a dehydration condensation agent by dissolving or suspending it in an organic solvent such as dimethylbormamide or pyridine.
The compound (1)'e of the present invention can be obtained by reaction with an ester activator such as PA), especially by adding 6-amidino-2-naphthol, preferably an acid addition salt thereof.
例えば、脱水縮合剤としてDOO’i用いる場合、カル
ボン酸誘導体(1)をピリジン等の溶媒に加え、ここに
6−アミジノ−2−ナフトール(1)Th加え一306
C〜+80℃、好ましくは室温でかくはんする。反応は
3〜5時間で終了するが、−晩反応させ【もさしつかえ
ない。反応終了後はジシクロへキシルウレア(DOU)
カ析出する。For example, when using DOO'i as a dehydration condensation agent, the carboxylic acid derivative (1) is added to a solvent such as pyridine, and 6-amidino-2-naphthol (1) Th is added thereto.
Stir at C to +80°C, preferably at room temperature. The reaction will be completed in 3 to 5 hours, but it may be allowed to react overnight. After the reaction is complete, dicyclohexylurea (DOU)
Precipitate.
なお、反応終了後反応液中に本発明化合物(1)が同時
に析出してくる場合と、溶媒中に溶けている場合がある
。前者の場合は析出物を濾取し、これ’i DMIF等
の適当な溶媒に加え、不溶性のDOU ’+!−濾去し
、濾液にエチルエーテル、酢酸エチル、アセトン等の溶
媒を加え、析出物全濾取することにより本発明化合物(
1)を得ることができる。または、析出物を濾取し、こ
れiDMF、水等の適当な溶媒に加え、不溶性のDOU
i濾去し、濾液を飽和NaHOO3水溶液に加えるこ
とにより本発明化合物(1) ’に炭酸塩として得るこ
とができる。In addition, the compound (1) of the present invention may precipitate simultaneously in the reaction solution after the completion of the reaction, or may dissolve in the solvent. In the former case, the precipitate is collected by filtration, added to a suitable solvent such as DMIF, and insoluble DOU '+! -The compound of the present invention (
1) can be obtained. Alternatively, the precipitate is collected by filtration and added to an appropriate solvent such as iDMF or water to remove insoluble DOU.
The compound (1)' of the present invention can be obtained as a carbonate by filtering it off and adding the filtrate to a saturated aqueous NaHOO3 solution.
また、後者の場合は、DOU’i濾去し、濾液にエーテ
ル、アセトン、酢酸エチル等の溶媒を加えることにより
本発明化合物(1)を得ることができる。In the latter case, the compound (1) of the present invention can be obtained by filtering off DOU'i and adding a solvent such as ether, acetone, or ethyl acetate to the filtrate.
また、他の製造方法として酸ハライドをカルボン酸誘導
体(璽)の反応性中間体として使用する場合、カルボン
酸誘導体(1) ’ik、sooノ2.5OBr2、P
OJ、等の酸ハロゲン化剤と反応させ、式(IT)で示
される
( R1,R,、R3およびR4は前述の通りであり、
Xはハロゲンを示す。)
酸ハロゲン化物を合成し、これを6−アミジノ−2−ナ
フトール(1)、好ましくはその酸付加塩を溶解したジ
メチルホルムアミド、ピリジン、ジメチルスルホキサイ
ド等の溶液に加え、脱ハロゲン化水素剤の存在下で反応
させることにより製造できる。In addition, as another production method, when acid halide is used as a reactive intermediate of carboxylic acid derivative (1), 'ik, soo 2.5OBr2, P
is reacted with an acid halogenating agent such as OJ, and is represented by the formula (IT) (R1, R,, R3 and R4 are as described above,
X represents halogen. ) Synthesize an acid halide, add it to a solution of dimethylformamide, pyridine, dimethyl sulfoxide, etc. in which 6-amidino-2-naphthol (1), preferably its acid addition salt, is dissolved, and add it to a solution of a dehydrohalogenating agent. It can be produced by reacting in the presence of.
脱ハロゲン化水素剤としては、炭酸カリウム、炭酸ナト
リウム、水酸化ナトリウム等の如き無機塩基、トリエチ
ルアミン、Vリジン、ジメチルアニリン等の如ぎ有機塩
基を使用し得るが、ピリジンが好ましい。反応は、−6
0℃〜+80℃の温度で容易に進行するが、副生成物の
生成を避ける意味で、反応を、初期には水冷下で行ない
、次いで室温下で行うのが好ましい。また、反応は2時
間ないし5時間で終了するが、−晩反応させてもさしつ
かえない。As the dehydrohalogenating agent, inorganic bases such as potassium carbonate, sodium carbonate, sodium hydroxide, etc., organic bases such as triethylamine, V-lysine, dimethylaniline, etc. can be used, but pyridine is preferred. The reaction is -6
Although the reaction easily proceeds at temperatures of 0°C to +80°C, in order to avoid the formation of by-products, it is preferable to carry out the reaction initially under water cooling and then at room temperature. Further, although the reaction is completed in 2 to 5 hours, it is also possible to carry out the reaction overnight.
反応終了後は反応混合物を、通常の処理方法で処理する
。例えば、ピリジンを反応溶媒として使用した場合には
、反応液にエチルエーテル、酢酸エチル等の溶媒を加え
析出する固型物を適当な溶媒、例えばメタノールとエチ
ルエーテルの混合物から再結晶することにより本発明化
合物(I)′fr:得ることができる。After the reaction is completed, the reaction mixture is treated by a conventional treatment method. For example, when pyridine is used as a reaction solvent, a solvent such as ethyl ether or ethyl acetate is added to the reaction solution, and the precipitated solid is recrystallized from an appropriate solvent, such as a mixture of methanol and ethyl ether. Invention compound (I)'fr: can be obtained.
また、化合物(1)の代りに、化合物(1)のアミジノ
基が保護されている化合物を、化合物(川)と反応させ
、化合物(1)のアミジノ基が保護されている化合物を
得ることができる。この化合物から、アミジノ基保護基
を通常の方法で脱離させて、本発明化合物(1) を得
ることができる。Alternatively, instead of compound (1), a compound in which the amidino group of compound (1) is protected can be reacted with the compound (Kawa) to obtain a compound in which the amidino group of compound (1) is protected. can. The compound (1) of the present invention can be obtained from this compound by removing the amidino group protecting group by a conventional method.
ここでいうアはジノ基保護基とは通常使用される保護基
でよい。その例として、ベンジルオキシカルがニル基、
t−ブトキシカルボニル基を挙げることができる。Here, the dino-protecting group may be a commonly used protecting group. For example, benzyloxycar is a nyl group,
Mention may be made of t-butoxycarbonyl group.
脱離方法の例として、パラジウム炭素による還元的脱離
、トリフルオロ酢酸またはHBr /酢酸による脱離な
どが挙げられる。Examples of desorption methods include reductive desorption with palladium on carbon, desorption with trifluoroacetic acid or HBr2/acetic acid, and the like.
また、所望により、通常の処理方法により、他の酸付加
塩を得ることができる。例えば、本発明化合物の炭酸塩
をメタノール、DMF等の溶媒に溶解またはけんだ<シ
、ここに、メタンスルホン酸、塩酸等の酸を加えて、炭
酸塩を溶解させ、得られた溶液に、エチルエーテル、酢
酸エチル等の溶媒を加えると、対応する酸付加塩が得ら
れる。使用し得る酸には、医薬として使用可能な塩酸、
硫酸、リン酸等の如き無機酸、酢酸、乳酸、クエン酸、
メタンスルホン酸、コハク酸、フマル酸、マレイン酸等
の如き有機酸がある。Other acid addition salts can also be obtained, if desired, by conventional processing methods. For example, a carbonate of the compound of the present invention is dissolved or suspended in a solvent such as methanol or DMF, an acid such as methanesulfonic acid or hydrochloric acid is added thereto to dissolve the carbonate, and the resulting solution is Addition of a solvent such as ethyl ether or ethyl acetate provides the corresponding acid addition salt. Acids that can be used include pharmaceutically usable hydrochloric acid;
Inorganic acids such as sulfuric acid, phosphoric acid, etc., acetic acid, lactic acid, citric acid,
Organic acids such as methanesulfonic acid, succinic acid, fumaric acid, maleic acid, etc.
本発明の化合物およびその医薬として使用可能な酸付加
塩は蛋白分解酵累であるトリプシン、ノラスミン、カリ
クレイン、スロンビンに対し強い阻害活性を有しており
膵炎の治療等に有効な効トリプシソ剤、出血性疾患の治
療に有効な抗プラスミン剤、抗カリクレイン剤、血栓等
の治療に有効な抗スロンビン剤として有用な化合物であ
る。The compounds of the present invention and their pharmaceutically usable acid addition salts have strong inhibitory activity against trypsin, nolasmin, kallikrein, and thrombin, which are proteolytic enzymes, and are effective trypsin agents for the treatment of pancreatitis, bleeding, etc. It is a useful compound as an anti-plasmin agent, an anti-kallikrein agent, effective in the treatment of sexual diseases, and an anti-thrombin agent, effective in the treatment of thrombosis, etc.
本発明化合物およびその医薬として使用可能な酸付加塩
は強いC1エステラーゼ(Olr + 01” )阻害
活性および補体溶血阻止作用を有している。The compounds of the present invention and their pharmaceutically usable acid addition salts have strong C1 esterase (Olr + 01'') inhibitory activity and complement hemolysis inhibiting activity.
このことは、補体の関寿した腎炎等のアレルヤー性疾患
に有効な抗補体剤として有用であることを示し【いる。This indicates that it is useful as an anti-complement agent effective for allergic diseases such as complement-related nephritis.
次に実施例により本発明化合物の製造方法をさらに詳細
に説明する。Next, the method for producing the compound of the present invention will be explained in more detail with reference to Examples.
なお、各化合物の物理恒数は表1に示す。Note that the physical constants of each compound are shown in Table 1.
実施例1(化合物Nn5)
6−アミジノ−2−ナフチル2−メトキシ−4−((4
,5−ジヒドロ−1H−イミダゾール−2−イル)アミ
ノコ−ベンゾエートの合成2−メトキシ−4−[:(4
,5−ジヒrロー1H−イミダゾール−2−イル)アミ
ノコ−安息香酸・塩酸塩165岬、6−アミジノ−2−
ナフトールメタンスルホネート178t+p、 DOO
173キおよび乾燥ピリジン0.5−の混合物を室温下
4時間攪拌する。アセトン50m1f加え攪拌後指出物
を濾取する。濾取物をジメチルホルムアミド20M1中
に添加し、攪拌する。不溶物全濾去後、濾液を氷冷エー
テル200dに攪拌下加える。析出物を濾取し飽和炭酸
水素す) IJウム水溶液60WLlに加え、10分間
攪拌する。析出する粉末を濾取し、十分水およびアセト
ンで洗浄後、濃塩酸0.2mlおよびアセトン5〇−中
に添加し、攪拌する。析出物を濾取し、エタノール5r
xlK溶解後、エーテル2011gを加え30分間攪拌
することにより、6−アミジノ−2−ナフチル 2−メ
トキシ−4−[:(4,5−ジヒドロ−1H−イミダゾ
ール−2−イル)アミノコ−ベンゾエート・二塩酸塩2
2キヲ淡黄色粉末として得る。Example 1 (Compound Nn5) 6-amidino-2-naphthyl 2-methoxy-4-((4
Synthesis of 2-methoxy-4-[:(4
,5-dihyro1H-imidazol-2-yl)aminoco-benzoic acid hydrochloride 165, 6-amidino-2-
Naphthol methanesulfonate 178t+p, DOO
A mixture of 173 and dry pyridine is stirred at room temperature for 4 hours. After adding 50ml of acetone and stirring, the residue was collected by filtration. Add the filtered material to 20M1 dimethylformamide and stir. After all insoluble matters were removed by filtration, the filtrate was added to 200 d of ice-cold ether with stirring. The precipitate was collected by filtration, added to 60 WL of an aqueous solution of saturated hydrogen carbonate, and stirred for 10 minutes. The precipitated powder is collected by filtration, washed thoroughly with water and acetone, and then added to 0.2 ml of concentrated hydrochloric acid and 50 mL of acetone, and stirred. Collect the precipitate by filtration and add 5 liters of ethanol.
After dissolving the hydrochloride 2
Two kilograms were obtained as a pale yellow powder.
実施例2(化合物NQ9)
6−アミジノ−2−ナフチル 2−フルオロ−4−[(
4,5〜ジヒドロ−1H−イミダゾール−2−フルオロ
−4−((4,5−ジヒドロ−1H−イミダゾール−2
−イル)アミノコ−安息香酸・塩酸塩600岬、6−ア
ミジノ−2−ナフトールメタンスルホネート522tu
z、4−ジメチルアミノぎりジン′50■およびDOO
620gfに乾燥ピリジン5 d ’ft加え室温下−
昼夜攪拌する。上澄みを傾斜で除去し、少量のぎりジン
を加え、摩砕した後上澄みを傾斜で除去する。アセトン
?加え攪拌し析出した粉末を濾取する。濾取物を熱水で
溶解し不溶物を濾去する。濾液に飽和炭酸水素ナトリウ
ム水溶液を加え析出物を濾取する。水洗後真空乾燥した
後、濃塩酸2m1f加える。この溶液を30分攪拌した
後、アセトンを加え更に30分攪拌する。析出物を濾取
しエタノール5耐に溶解後、アセトン54分加え30分
攪拌することにより、6−アミジノ−2−ナフチル 2
−フルオロ600qを無色粉末として得る。Example 2 (Compound NQ9) 6-amidino-2-naphthyl 2-fluoro-4-[(
4,5-dihydro-1H-imidazole-2-fluoro-4-((4,5-dihydro-1H-imidazole-2
-yl)aminoco-benzoic acid hydrochloride 600 cape, 6-amidino-2-naphthol methanesulfonate 522tu
z,4-dimethylaminogiridine'50■ and DOO
Add 5 d'ft of dry pyridine to 620 gf at room temperature.
Stir day and night. The supernatant is removed by decanting, a small amount of girijin is added, and after grinding, the supernatant is removed by decanting. acetone? The powder was added and stirred, and the precipitated powder was collected by filtration. The filtered material is dissolved in hot water and the insoluble matter is filtered off. A saturated aqueous sodium hydrogen carbonate solution is added to the filtrate, and the precipitate is collected by filtration. After washing with water and vacuum drying, 2ml of concentrated hydrochloric acid is added. After this solution was stirred for 30 minutes, acetone was added and stirred for an additional 30 minutes. The precipitate was collected by filtration, dissolved in 5-proof ethanol, and then acetone was added for 54 minutes and stirred for 30 minutes to obtain 6-amidino-2-naphthyl 2.
- Fluoro 600q is obtained as a colorless powder.
実施例1および2の方法と同様にして表1のその他の化
合物を得る。The other compounds in Table 1 are obtained analogously to the methods of Examples 1 and 2.
Claims (1)
〜6個の直鎖または分枝鎖アルキル基を示し、R_3は
炭素数1〜6個の直鎖または分枝鎖アルキル基を示すか
、あるいはR_1とR_3は環を形成してもよく、その
場合二重結合を介してもよく、そして R_4は炭素数1〜6個の直鎖または分枝鎖アルキル基
、アルコキシ基またはハロゲンを示す)で示される化合
物およびその医薬として使用可能な酸付加塩。[Claims] Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula, R_1 and R_2 each represent hydrogen or 1 carbon number.
~ 6 straight-chain or branched alkyl groups, R_3 represents a straight-chain or branched alkyl group having 1 to 6 carbon atoms, or R_1 and R_3 may form a ring, which and R_4 represents a straight or branched alkyl group having 1 to 6 carbon atoms, an alkoxy group, or a halogen) and their pharmaceutically usable acid addition salts. .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12834085A JPS61286362A (en) | 1985-06-14 | 1985-06-14 | Amidine compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12834085A JPS61286362A (en) | 1985-06-14 | 1985-06-14 | Amidine compound |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS61286362A true JPS61286362A (en) | 1986-12-16 |
Family
ID=14982377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP12834085A Pending JPS61286362A (en) | 1985-06-14 | 1985-06-14 | Amidine compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61286362A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6388122B1 (en) | 1996-04-10 | 2002-05-14 | Ono Pharmaceutical Co., Ltd. | Tryptase inhibitor and novel guanidino derivatives |
-
1985
- 1985-06-14 JP JP12834085A patent/JPS61286362A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6388122B1 (en) | 1996-04-10 | 2002-05-14 | Ono Pharmaceutical Co., Ltd. | Tryptase inhibitor and novel guanidino derivatives |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2134901A (en) | Amidine compounds | |
PT90623B (en) | PROCESS FOR THE PREPARATION OF UTERIC N-HETEROCYCLYL-4-GUANILALYL-BENZAMIDES AS PROTEASE INHIBITORS | |
HU176251B (en) | Process for producing 2,4,6-triiodo-benzoic acid derivatives substituted with 2,4,6-triiodo-benzoyl-amino-alkyl-acetamido group | |
JP4230453B2 (en) | Novel prodrugs of 1-methyl-2- (4-amidinophenylaminomethyl) -benzimidazol-5-yl-carboxylic acid- (N-2-pyridyl-N-2-hydroxycarbonylethyl) -amide, their preparation And their use as pharmaceutical compositions | |
US4820730A (en) | 6-amino-2-naphthyl 4-gusnichinobenzoate derivatives and pharmaceutical composition containing them | |
CA2583920C (en) | Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | |
JPS6053027B2 (en) | Tetrazole derivative | |
JPS60142981A (en) | 3-indolecarboxamide derivative | |
JPS596861B2 (en) | Method for producing 5-[(2-halogeno-1-hydroxy)alkyl[carbostyryl derivative] | |
JPS61286361A (en) | Amidine derivative | |
JPH04217950A (en) | Hydroxamic acid derivative, enzyme inhibitor and antiulcer agent | |
NO130583B (en) | ||
JPS61286362A (en) | Amidine compound | |
JP3489116B2 (en) | New synthetic intermediates and methods for producing aminopiperazine derivatives | |
AU675035B2 (en) | Benzene derivatives and pharmaceutical composition | |
GB2096598A (en) | Novel amidine compounds | |
JPH0446148A (en) | 4-guadininobenzoic phenyl ester derivative and protease inhibitor containing the same | |
CN107365299B (en) | Preparation method of dabigatran etexilate and intermediate thereof | |
JPS63227573A (en) | Pyrimidinylpropionic acid derivative | |
JPH07242624A (en) | New azetidinone derivative | |
JPH04154768A (en) | New isoquinoline derivative or its acid addition salt | |
JPS6324994B2 (en) | ||
JPH024588B2 (en) | ||
JPS60246384A (en) | Chromone-8-carpoxamide derivative | |
JPS62111963A (en) | P-guanidinobenzoic acid thiophenyl ester derivative and pharmaceutical containing same |